RCBTB1

Summary

Gene Symbol: RCBTB1
Description: RCC1 and BTB domain containing protein 1
Alias: CLLD7, CLLL7, GLP, RDEOA, RCC1 and BTB domain-containing protein 1, CLL deletion region gene 7 protein, GDP/GTP exchange factor (GEF)-like protein, chronic lymphocytic leukemia deletion region gene 7 protein, regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 1, regulator of chromosome condensation and BTB domain-containing protein 1
Species: human

Top Publications

  1. ncbi A novel angiotensin II type 1 receptor-associated protein induces cellular hypertrophy in rat vascular smooth muscle and renal proximal tubular cells
    Deng Fu Guo
    Department of Medicine, University of Montreal and Research Center, CHUM Hotel Dieu Hospital, 3850 St Urbain, Montreal, Quebec H2W 1T8, Canada
    J Biol Chem 279:21109-20. 2004
  2. ncbi Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation
    J Buteau
    Molecular Nutrition Unit, Department of Nutrition, University of Montreal, the Centre de Recherche du CHUM and Institut du Cancer, Montreal, Quebec, Canada
    Diabetes 50:2237-43. 2001
  3. ncbi Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects
    Juris J Meier
    Department of Medicine, Ruhr University, Bochum, Germany
    Diabetes 54:2212-8. 2005
  4. ncbi Plasma and intestinal concentrations of GIP and GLP-1 (7-36) amide during suckling and after weaning in pigs
    J M Knapper
    School of Biological Sciences, University of Surrey, Guildford, United Kingdom
    Horm Metab Res 27:485-90. 1995
  5. ncbi Proteolytic cleavage of glucagon-like peptide-1 by pancreatic beta cells and by fetal calf serum analyzed by mass spectrometry
    H Tammen
    The Lower Saxony Institute for Peptide Research (IPF, Hannover, Germany
    J Chromatogr A 852:285-95. 1999
  6. doi Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus
    Joy Cuthbertson
    Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, BT126BA Northern Ireland, UK
    Metabolism 60:52-6. 2011
  7. ncbi Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus
    M A Nauck
    , Knappschaftskrankenhaus Bochum, Germany
    Horm Metab Res 29:411-6. 1997
  8. doi The effect of glucagon-like peptide 2 injection on performance, small intestinal morphology, and nutrient transporter expression of stressed broiler chickens
    X F Hu
    The State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing 100193, P R China
    Poult Sci 89:1967-74. 2010
  9. ncbi Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity
    L R Ranganath
    Department of Chemical Pathology, Epsom General Hospital, Surrey, UK
    Horm Metab Res 31:262-6. 1999
  10. ncbi Urinary excretion of glucagon-like peptide 1 (GLP-1) 7-36 amide in human type 2 (non-insulin-dependent) diabetes mellitus
    R Lugari
    Department of Endocrinology, University of Parma, Via Gramsci 14, 43100 Parma, Italy
    Horm Metab Res 33:568-71. 2001

Detail Information

Publications570 found, 100 shown here

  1. ncbi A novel angiotensin II type 1 receptor-associated protein induces cellular hypertrophy in rat vascular smooth muscle and renal proximal tubular cells
    Deng Fu Guo
    Department of Medicine, University of Montreal and Research Center, CHUM Hotel Dieu Hospital, 3850 St Urbain, Montreal, Quebec H2W 1T8, Canada
    J Biol Chem 279:21109-20. 2004
    ..These findings may provide new molecular mechanisms to understand hypertrophic agents such as angiotensin II-induced cellular hypertrophy...
  2. ncbi Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation
    J Buteau
    Molecular Nutrition Unit, Department of Nutrition, University of Montreal, the Centre de Recherche du CHUM and Institut du Cancer, Montreal, Quebec, Canada
    Diabetes 50:2237-43. 2001
    Glucagon-like peptide-1 (GLP-1), an insulinotropic and glucoincretin hormone, is a potentially important therapeutic agent in the treatment of diabetes...
  3. ncbi Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects
    Juris J Meier
    Department of Medicine, Ruhr University, Bochum, Germany
    Diabetes 54:2212-8. 2005
    Glucagon-like peptide 1 (GLP-1) has been proposed to act as an incretin hormone due to its ability to enhance glucose-stimulated insulin secretion...
  4. ncbi Plasma and intestinal concentrations of GIP and GLP-1 (7-36) amide during suckling and after weaning in pigs
    J M Knapper
    School of Biological Sciences, University of Surrey, Guildford, United Kingdom
    Horm Metab Res 27:485-90. 1995
    Plasma concentrations of glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(7-36)amide (GLP-1[7-36]amide) were measured after milk ingestion in 15-18 day old piglets and after weaning diet ingestion in 33 day ..
  5. ncbi Proteolytic cleavage of glucagon-like peptide-1 by pancreatic beta cells and by fetal calf serum analyzed by mass spectrometry
    H Tammen
    The Lower Saxony Institute for Peptide Research (IPF, Hannover, Germany
    J Chromatogr A 852:285-95. 1999
    ..a beta-cell line exhibit a proteolytic activity essential for the biological function of glucagon-like peptide-1 (GLP-1)...
  6. doi Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus
    Joy Cuthbertson
    Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, BT126BA Northern Ireland, UK
    Metabolism 60:52-6. 2011
    Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus...
  7. ncbi Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus
    M A Nauck
    , Knappschaftskrankenhaus Bochum, Germany
    Horm Metab Res 29:411-6. 1997
    ..examining small groups of type 2-(NIDDM) diabetic patients have shown the potential of glucagon-like peptide 1 (GLP-1) to normalize fasting hyperglycaemia...
  8. doi The effect of glucagon-like peptide 2 injection on performance, small intestinal morphology, and nutrient transporter expression of stressed broiler chickens
    X F Hu
    The State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing 100193, P R China
    Poult Sci 89:1967-74. 2010
    An experiment was conducted to determine the effect of injecting glucagon-like peptide 2 (GLP-2) on the small intestinal weight, morphology, and nutrient transporter expression in pharmacologically stressed broiler chickens...
  9. ncbi Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity
    L R Ranganath
    Department of Chemical Pathology, Epsom General Hospital, Surrey, UK
    Horm Metab Res 31:262-6. 1999
    ..insulin and insulinotropic hormone (glucose-dependent insulinotropic polypeptide, GIP; glucagon-like peptide-1, GLP-1) secretion on the activation of lipoprotein lipase (LPL) in six lean and six obese age-matched women...
  10. ncbi Urinary excretion of glucagon-like peptide 1 (GLP-1) 7-36 amide in human type 2 (non-insulin-dependent) diabetes mellitus
    R Lugari
    Department of Endocrinology, University of Parma, Via Gramsci 14, 43100 Parma, Italy
    Horm Metab Res 33:568-71. 2001
    The urinary excretion of insulinotropic glucagon-like peptide 1 (GLP-1) was investigated as an indicator of renal tubular integrity in 10 healthy subjects and in 3 groups of type 2 diabetic patients with different degrees of urinary ..
  11. ncbi The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
    A Flint
    Research Department of Human Nutrition, Center for Food Research, The Royal Veterinary and Agricultural University, Rolighedsvej 30, DK 1958 Frederiksberg C, Denmark
    Int J Obes Relat Metab Disord 25:781-92. 2001
    Peripheral infusions of glucagon-like peptide-1 (GLP-1) in humans have been shown to inhibit gastrointestinal motility and decrease hunger and energy intake. However, these investigations used supraphysiological doses...
  12. ncbi Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells
    Younes Anini
    Department of Physiology, Medical Sciences Building, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8
    Endocrinology 144:3244-50. 2003
    Glucagon-like peptide 1 (GLP-1) released from distal intestinal endocrine L cells after food intake is a potent glucose-dependent stimulant of insulin secretion...
  13. ncbi Amphibian glucagon family peptides: potent metabolic regulators in fish hepatocytes
    T P Mommsen
    Department of Biochemistry and Microbiology, University of Victoria, P O Box 3055, V8W 3P6, Victoria, BC, Canada
    Regul Pept 99:111-8. 2001
    Peptides analogous to glucagon-like peptide-1 (GLP-1) have been isolated from amphibian pancreas and intestine, and their amino acid sequences and cDNA structures elucidated...
  14. ncbi Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University, Bochum, Germany
    Gastroenterology 130:44-54. 2006
    The gut-derived peptide glucagon-like peptide 2 (GLP-2) has been suggested as a potential drug candidate for the treatment of various intestinal diseases...
  15. doi Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome
    Ida B Gottschalck
    Sanos Bioscience, Copenhagen, Denmark
    Scand J Gastroenterol 43:1304-10. 2008
    The gut hormone GLP-2 (glucagon-like peptide-2) seems to be involved in the circadian pattern of bone resorption, whereas parathyroid hormone (PTH) is an established key hormone in bone turnover...
  16. doi Expression of mRNA for proglucagon and glucagon-like peptide-2 (GLP-2) receptor in the ruminant gastrointestinal tract and the influence of energy intake
    C C Taylor-Edwards
    Department of Animal and Food Sciences, University of Kentucky, Lexington, KY, USA
    Domest Anim Endocrinol 39:181-93. 2010
    Glucagon-like peptide-2 (GLP-2) is a potent trophic gut hormone, yet its function in ruminants is relatively unknown...
  17. ncbi Interaction of GLP-I and leptin at rat pancreatic B-cells: effects on insulin secretion and signal transduction
    H C Fehmann
    Department of Medicine, Philipps University of Marburg, Germany
    Horm Metab Res 29:572-6. 1997
    ..We characterized the direct interaction of GLP-I, an important incretin hormone, and leptin on insulin secretion and signal transduction in B-cells...
  18. ncbi Comparison of turbulent-flow chromatography with automated solid-phase extraction in 96-well plates and liquid-liquid extraction used as plasma sample preparation techniques for liquid chromatography-tandem mass spectrometry
    D Zimmer
    Bayer AG, Preclinical Pharmacokinetics, Wuppertal, Germany
    J Chromatogr A 854:23-35. 1999
    ..assays were fully validated for the application to toxicokinetics studies (compliant with Good Laboratory Practices-GLP). The limit of quantitation was 1...
  19. ncbi Enhanced secretion of glucagon-like peptide 1 by biguanide compounds
    Nobuyuki Yasuda
    Tsukuba Research Laboratories, Eisai Company Limited, 5 1 3, Tokodai, Tsukuba, Ibaraki, Japan
    Biochem Biophys Res Commun 298:779-84. 2002
    Metformin was reported to increase plasma active glucagon-like peptide-1 (GLP-1) in humans...
  20. ncbi Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas
    K Inoue
    Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan
    Horm Metab Res 23:407-9. 1991
    The effects of glucagon-like peptide 1 (7-36) amide [GLP-1 (7-36) amide] and glucagon on the release of islet amyloid polypeptide (IAPP), or amylin, from the isolated perfused rat pancreas were studied. In the presence of 5...
  21. ncbi Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus
    Kristine Juul Hare
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Denmark
    Dan Med Bull 57:B4181. 2010
    ..The aim was to investigate if GLP-1 induced glucagon inhibition was dose dependent and if suppression was equally potent in healthy controls and T2DM ..
  22. pmc Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
    P B Jeppesen
    Department of Gastroenterology, Copenhagen University Hospital Rigshospitalet, 2121 Copenhagen, Denmark
    Gastroenterol Res Pract 2009:425759. 2009
    Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study...
  23. ncbi Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes
    Claus B Juhl
    Medical Department M Endocrinology and Diabetes, Arhus University Hospital, Arhus, Denmark
    Diabetes 51:424-9. 2002
    Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential interest for the treatment of type 2 diabetes...
  24. ncbi Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus
    Steffen Runge
    Molecular Pharmacology, Novo Nordisk, DK 2760 Maaloev, Denmark
    J Biol Chem 278:28005-10. 2003
    The glucagon and glucagon-like peptide-1 (GLP-1) receptors are homologous family B seven-transmembrane (7TM) G protein-coupled receptors, and they selectively recognize the homologous peptide hormones glucagon (29 amino acids) and GLP-1 (..
  25. ncbi GLP-2 levels in infants with intestinal dysfunction
    David L Sigalet
    Division of Pediatrics, General Surgery, Alberta Children s Hospital, Calgary, AB, T2T 5C7, Canada
    Pediatr Res 56:371-6. 2004
    Glucagon Like Peptide 2 (GLP-2) has been proposed as an important regulatory hormone in nutrient absorption...
  26. ncbi Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract
    Ida B Gottschalck
    Sanos Bioscience, Copenhagen, Denmark
    Scand J Gastroenterol 43:929-37. 2008
    ..Glucagon-like peptide-2 (GLP-2) is a peptide secreted from endocrine L cells in the intestinal mucosa in relation to food-intake...
  27. pmc The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study
    Adam M Deane
    University of Adelaide, Discipline of Anaesthesia and Intensive Care, North Terrace, Adelaide, 5000 South Australia, Australia
    Crit Care 13:R67. 2009
    ..In healthy patients and those with type 2 diabetes, exogenous glucagon-like peptide-1 (GLP-1) decreases blood glucose by suppressing glucagon, stimulating insulin and slowing gastric emptying...
  28. ncbi Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats
    M I Lopez-Delgado
    Department of Metabolism, Nutrition and Hormones, Fundacion Jimenez Diaz, Madrid, Spain
    Endocrinology 139:2811-7. 1998
    Glucagon-like peptide 1(7-36)amide (GLP-1) is currently under investigation as a possible tool in the treatment of non-insulin-dependent diabetes mellitus...
  29. ncbi No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    Diabetes Care 26:2581-7. 2003
    Glucagon-like peptide 1 (GLP-1) is a proglucagon derivative secreted primarily from the L-cells of the small intestinal mucosa in response to the ingestion of meals. GLP-1 stimulates insulin secretion and inhibits glucagon secretion...
  30. ncbi Role of gastrointestinal hormones in postprandial reduction of bone resorption
    Dennis B Henriksen
    Nordic Bioscience, Herlev, Denmark
    J Bone Miner Res 18:2180-9. 2003
    ..Investigations led to a dose escalation study with glucagon like peptide-2 (GLP-2) in postmenopausal women. We found a dose-dependent effect of GLP-2 on the reduction of bone resorption.
  31. pmc Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Gut 54:1224-31. 2005
    Glucagon-like peptide 2 (GLP-2) may improve intestinal absorption in short bowel syndrome (SBS) patients with an end jejunostomy...
  32. ncbi Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients
    M A Nauck
    Department of Medicine, Ruhr University, Knappschafts Krankenhaus, Bochum, Germany
    Diabet Med 15:937-45. 1998
    Intravenous GLP-1 [7-36 amide] can normalize fasting hyperglycaemia in Type 2 diabetic patients...
  33. ncbi Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
    A Plamboeck
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetologia 48:1882-90. 2005
    The incretin hormone glucagon-like peptide 1 (GLP-1) has antihyperglycaemic effects, but its therapeutic usefulness is limited by its metabolic instability...
  34. ncbi Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts
    Kerem Bulut
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Germany
    Eur J Pharmacol 578:279-85. 2008
    Glucagon like peptide-2 (GLP-2) exerts intestinotrophic actions, but the underlying mechanisms are still a matter of debate...
  35. pmc Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents
    June Zhou
    Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
    Am J Physiol Endocrinol Metab 295:E1160-6. 2008
    Glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) are anti-diabetes/obesity hormones secreted from the gut after meal ingestion...
  36. ncbi GLP-1 (7-36) amide: effects on glucose transport and metabolism in rat adipose tissue
    A Perea
    Department of Metabolism, Nutrition and Hormones, , Madrid, Spain
    Horm Metab Res 29:417-21. 1997
    In rat adipocytes, GLP-1 (7-36) amide induced an increment in 2-deoxy-glucose uptake, which was additive to that of insulin...
  37. ncbi Glucagon-like peptide containing pathways in the regulation of feeding behaviour
    M Tang-Christensen
    Department of Medical Anatomy Sect B, University of Copenhagen, Copenhagen, Denmark
    Int J Obes Relat Metab Disord 25:S42-7. 2001
    The pre-proglucagon derived peptides, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are both involved in a wide variety of peripheral functions, such as glucose homeostasis, gastric emptying, intestinal growth, ..
  38. doi Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat
    V Bucinskaite
    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Neurogastroenterol Motil 21:978-e78. 2009
    The vagus nerve plays a role in mediating effects of the two glucagon-like peptides GLP-1 and GLP-2 on gastrointestinal growth, functions and eating behaviour...
  39. pmc MSP and GLP-1/Notch signaling coordinately regulate actomyosin-dependent cytoplasmic streaming and oocyte growth in C. elegans
    Saravanapriah Nadarajan
    Department of Genetics, Cell Biology and Development, University of Minnesota, 6 160 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, USA
    Development 136:2223-34. 2009
    ..In C. elegans, we show that GLP-1/Notch signaling functions in the germline to modulate oocyte growth when sperm are available for fertilization ..
  40. doi Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice
    Giovanni Pacini
    Metabolic Unit, Institute of Biomedical Engineering, National Research Council, Padova, Italy
    Metabolism 59:988-92. 2010
    Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) potently augment insulin response to glucose...
  41. ncbi New physiological effects of the incretin hormones GLP-1 and GIP
    Meena Asmar
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Denmark
    Dan Med Bull 58:B4248. 2011
    ..Scientific interest in recent years has concentrated on both the secretion and function of the incretin hormones, GLP-1 and GIP, and their suitability as new target drugs...
  42. pmc Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice
    J Thulesen
    Department of Medical Anatomy, Section B, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Gut 53:1145-50. 2004
    Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity...
  43. doi Expression of proglucagon and proglucagon-derived peptide hormone receptor genes in the chicken
    Mark P Richards
    Animal Biosciences and Biotechnology Laboratory, USDA, ARS, Animal and Natural Resources Institute, Beltsville Agricultural Research Center, BARC East, Beltsville, MD 20705 2350, USA
    Gen Comp Endocrinol 156:323-38. 2008
    ..strategy to sequence and characterize the chicken proglucagon gene that encodes glucagon, glucagon-like peptide (GLP)-1 and GLP-2...
  44. ncbi Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats
    P J Larsen
    Laboratory of Obesity Research, Center for Clinical and Basic Research, Ballerup, Denmark
    Diabetes 50:2530-9. 2001
    Postprandial release of the incretin glucagon-like peptide-1 (GLP-1) has been suggested to act as an endogenous satiety factor in humans...
  45. ncbi The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients
    L Juntti-Berggren
    Department of Molecular Medicine, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
    Diabetes Care 19:1200-6. 1996
    To investigate the long-term antidiabetogenic effect of glucagon-like peptide 1 (GLP-1) and its influence on diabetic dyslipoproteinemia, patients with NIDDM were treated with GLP-1 subcutaneously for 1 week.
  46. ncbi Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion
    N Pørksen
    Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus C, Denmark
    Diabetes 47:45-9. 1998
    Glucagon-like peptide 1 (GLP-1) is a peptide hormone that is released from the gut after luminal stimulation. The hormone is a potent insulin secretagogue and is a potential novel pharmaceutical adjuvant in the treatment of NIDDM...
  47. ncbi Evaluation of beta-cell secretory capacity using glucagon-like peptide 1
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Diabetes Care 23:807-12. 2000
    Beta-cell secretory capacity is often evaluated with a glucagon test or a meal test. However, glucagon-like peptide 1 (GLP-1) is the most insulinotropic hormone known, and the effect is preserved in type 2 diabetic patients.
  48. doi The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
    Asger Lund
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    Am J Physiol Endocrinol Metab 300:E1038-46. 2011
    ..the role of the intestinal hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) in this discrepancy...
  49. ncbi Potentiation of the insulinotropic action of GLP-1 by succinic acid dimethyl ester in fed anaesthetized rats
    J A Garcia-Martinez
    Fundació6n Jiménez Diaz, Madrid, Spain
    Horm Metab Res 32:306-9. 2000
    The insulinotropic action of GLP-1 is modulated by the nutritional environment of islet B-cells. This study explores whether an ester of succinic acid could be used to potentiate the insulin secretory response to GLP-1 in vivo...
  50. ncbi Interaction of glucagon-like peptide-I (7-37) and somatostatin-14 on signal transduction and proinsulin gene expression in beta TC-1 cells
    H C Fehmann
    Department of Internal Medicine, Philipps University of Marburg, Germany
    Metabolism 43:787-92. 1994
    The interactions of glucagon-like peptide-I(7-37)/(7-36)amide (GLP-I) and somatostatin-14 were characterized on the cyclic adenosine monophosphate (cAMP)-dependent signal transduction pathway and on proinsulin gene expression using mouse ..
  51. pmc Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
    J Schirra
    Clinical Research Unit for Gastrointestinal Endocrinology and Department of Gastroenterology and Endocrinology, Philipps University, 35033 Marburg, Germany
    J Clin Invest 101:1421-30. 1998
    The gastrointestinal hormone, glucagon-like peptide-1(7-36)amide (GLP-1) is released after a meal...
  52. ncbi Evolution of new hormone function: loss and gain of a receptor
    D M Irwin
    Department of Laboratory Medicine and Pathobiology, Banting and Best Diabetes Centre, University of Toronto, 100 College St, Toronto, Ontario, Canada M5G lL5
    J Hered 96:205-11. 2005
    The vertebrate proglucagon gene encodes three glucagon-like sequences (glucagon, glucagon-like peptide-1 [GLP-1], and glucagon-like peptide 2 [GLP-2]) that have distinct functions in regulating metabolism in mammals...
  53. ncbi The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
    Juris J Meier
    Dept of Medicine I, St Josef Hospital, Ruhr Univ Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Am J Physiol Endocrinol Metab 290:E1118-23. 2006
    Glucagon-like peptide 1 (GLP-1) lowers glycemia by modulating gastric emptying and endocrine pancreatic secretion. Rapidly after its secretion, GLP-1-(7-36) amide is degraded to the metabolite GLP-1-(9-36) amide...
  54. ncbi Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals
    Ludwik K Malendowicz
    Department of Histology and Embryology, School of Medicine, Poznan, Poland
    Int J Mol Med 10:327-31. 2002
    ..We have investigated the acute effects of preproglucagon derived peptides (PGDP) - glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and exendin-4 (EX4), a GLP-1 receptor agonist, on thyrotropin (TSH) secretion ..
  55. ncbi Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1
    Michael A Nauck
    Medizinische Klinik 1, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstr 56, D 44791 Bochum, Germany
    Regul Pept 118:89-97. 2004
    It was the aim of the study to examine whether the insulinotropic gut hormone GLP-1 is able to control or even normalise glycaemia in healthy subjects receiving intravenous glucose infusions and in severely ill patients hyperglycaemic ..
  56. pmc Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Denmark
    Gut 47:370-6. 2000
    The glucagon-like peptides (GLP) 1 and 2 are secreted postprandially from L cells located mainly in the ileum. Both hormones prolong intestinal transit and GLP-2 is intestinotrophic in rodents...
  57. ncbi Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety
    P T Schmidt
    Department of Gastroenterology and Hepatology, Karolinska Hospital, Karolinska Institutet, SE 171 76, Stockholm, Sweden
    Regul Pept 116:21-5. 2003
    Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted in parallel to the circulation after a meal. Intravenous (IV) GLP-1 has an inhibitory effect on gastric emptying, hunger and food intake in man...
  58. ncbi Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
    George G Sokos
    Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
    Am J Cardiol 100:824-9. 2007
    ..Glucagon-like peptide-1 (GLP-1) is a naturally occurring peptide whose insulinotropic effects are predicated on the glucose concentration, ..
  59. ncbi [Effect of Ganoderma lucidum polysaccharides on intestinal mucosal immune system in H22 liver cancer bearing mice]
    Gui Qin Zhou
    Department of Integrative Medicine, Beijing Ditan Hospital, Beijing
    Zhongguo Zhong Xi Yi Jie He Za Zhi 29:335-9. 2009
    To observe the mucosal immune mechanism of anti-tumor action of Ganoderma lucidum polysaccharides (GLP).
  60. pmc GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells
    Julie Quoyer
    INSERM, U661, Equipe Avenir, CNRS, UMR5203, Institut de Genomique Fonctionnelle, Université Montpellier I and II, 34094 Montpellier Cedex 5, France
    J Biol Chem 285:1989-2002. 2010
    Strategies based on activating GLP-1 receptor (GLP-1R) are intensively developed for the treatment of type 2 diabetes...
  61. doi DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
    Philip A Read
    Department of Medicine, Cardiovascular Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    Circ Cardiovasc Imaging 3:195-201. 2010
    Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted postprandially that promotes myocardial glucose uptake...
  62. doi Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction
    Betsy B Dokken
    Department of Medicine, University of Arizona, Tucson, AZ, USA
    Resuscitation 81:755-60. 2010
    ..The aim of this study was to determine if glucagon-like peptide-1 (GLP-1) improves post-resuscitation myocardial microcirculatory function.
  63. doi The corn protein, zein hydrolysate, administered into the ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 secretion and dipeptidyl peptidase-IV activity in rats
    Taisuke Mochida
    Division of Bio systems and Sustainability, Graduate School of Agriculture, Hokkaido University, Sapporo, Japan 0608589
    Endocrinology 151:3095-104. 2010
    ..that a hydrolysate prepared from corn zein [zein hydrolysate (ZeinH)] strongly stimulates glucagons-like peptide-1 (GLP-1) secretion from the murine GLP-1-producing enteroendocrine cell line and in the rat small intestine, especially ..
  64. pmc Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients
    Michael R Rickels
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania School of Medicine, 700 Clinical Research Building, 415 Curie Boulevard, Philadelphia, Pennsylvania 19104 6149, USA
    J Clin Endocrinol Metab 94:181-9. 2009
    ..Glucose-dependent insulin secretion is often impaired after islet transplantation where reduced beta-cell secretory capacity indicates a low functional beta-cell mass...
  65. ncbi GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
    E Naslund
    Division of Surgery, Danderyd Hospital, Karolinska Institutet, SE 182 88, Stockholm, Sweden
    Am J Physiol 277:R910-6. 1999
    The aim of the present study was to assess the effect of glucagon-like peptide-1 (GLP-1) on solid gastric emptying and the subsequent release of pancreatic and intestinal hormones. In eight men [age 33.6 +/- 2.5 yr, body mass index 24...
  66. ncbi Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Diabetes 53:654-62. 2004
    Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential...
  67. ncbi The antagonistic metabolite of GLP-1, GLP-1 (9-36)amide, does not influence gastric emptying and hunger sensations in man
    Carl Frederic Nagell
    Department of Surgical Gastroenterology, Glostrup University Hospital, Denmark
    Scand J Gastroenterol 42:28-33. 2007
    Glucagon-like peptide-1 (GLP-1 (7-36)amide) is an intestinal hormone that is released in response to meal ingestion. GLP-1 reduces postprandial gastric and exocrine pancreatic secretion and is believed to inhibit gastric emptying...
  68. ncbi Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat
    David W Nelson
    Department of Nutritional Sciences, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    Endocrinology 148:1954-62. 2007
    Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent proglucagon-derived hormone that stimulates intestinal growth through poorly understood paracrine and/or neural pathways...
  69. ncbi Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
    Kirsten Vollmer
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Diabetes 57:678-87. 2008
    Defects in glucagon-like peptide 1 (GLP-1) secretion have been reported in some patients with type 2 diabetes after meal ingestion...
  70. doi Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice
    Roman Iakoubov
    Departments of Physiology, University of Toronto, Toronto, Ontario, Canada
    Endocrinology 150:4033-43. 2009
    Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent intestinotropic hormone that promotes intestinal growth, via increased intestinal proliferation and decreased apoptosis, as well as increases in nutrient absorption and barrier ..
  71. doi Glucagon-like peptide-1 inhibits voltage-gated potassium currents in mouse nodose ganglion neurons
    G G Gaisano
    Gastrointestinal Diseases Research Unit GIDRU, Department of Medicine, Queen s University, Kingston, ON, Canada
    Neurogastroenterol Motil 22:470-9, e111. 2010
    Glucagon-like peptide-1 (GLP-1) is a major hormone known to regulate glucose homeostasis and gut function, and is an important satiety mediator. These actions are at least in part mediated via an action on vagal afferent neurons...
  72. ncbi Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1
    Jocelyn de Heer
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Diabetes 56:438-43. 2007
    Glucagon-like peptide (GLP)-1 mimetics have been reported to cause hypoglycemia when combined with sulfonylureas...
  73. ncbi Improved high-performance liquid chromatographic determination of amoxicillin in human plasma by means of column switching
    P Muth
    Medical Biological Development, Heumann Pharma, , Germany
    J Chromatogr A 729:259-66. 1996
    ..4-0.0501 micrograms/ml) and the inter-day variation ranged from 2.0 to 4.5%. The method was validated according to GLP guidelines and its suitability was demonstrated by the analysis of several hundred samples in a bioequivalence ..
  74. ncbi Sensitive high-performance liquid chromatographic determination of arbidol, a new antiviral compound, in human plasma
    R Metz
    Heumann Pharma, , Germany
    J Chromatogr A 810:63-9. 1998
    ..Linearity in plasma was proven over the whole calibration range (10.2-0.005 micrograms/ml). The method was validated according to GLP guidelines and its suitability was demonstrated by analysis of samples from a pharmacokinetic study.
  75. ncbi Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells
    R Göke
    Department of Internal Medicine, Philipps University of Marburg, Germany
    J Biol Chem 268:19650-5. 1993
    ..venom shows structural relationship to the important incretin hormone glucagon-like peptide 1-(7-36)-amide (GLP-1)...
  76. ncbi The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport
    C I Cheeseman
    Department of Physiology, University of Alberta, Edmonton, Canada
    Am J Physiol 271:G477-82. 1996
    The effect of gastric inhibitory polypeptide (GIP) and the related glucagon-like peptides-1 and -2 (GLP-1 and GLP-2) on jejunal basolateral membrane glucose transport was investigated to determine if the upregulation produced by luminal ..
  77. doi Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
    E U Graefe-Mody
    Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 65, D 88397 Biberach Riss, Germany
    Curr Med Res Opin 25:1963-72. 2009
    ..control in type 2 diabetic patients by increasing the half-life of the incretin hormone glucagon-like peptide-1 (GLP-1). Linagliptin is expected to be used as monotherapy or in combination with other antihyperglycaemic agents...
  78. doi Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis
    R Fan
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong SAR, China
    Diabetes Obes Metab 12:815-24. 2010
    Glucagon-like peptide-1 (GLP-1) stimulates beta-cell proliferation and enhances beta-cell survival, whereas oligomerization of human islet amyloid polypeptide (hIAPP) may induce beta-cell apoptosis and reduce beta-cell mass...
  79. doi GLP-1: what is known, new and controversial in 2010?
    R Burcelin
    Institut national de la santé et de la recherche médicale INSERM U858, Toulouse, France
    Diabetes Metab 36:503-9. 2010
    Over the past 2 years, more than 1300 manuscripts have been published on glucagon-like peptide-1 (GLP-1) and yet, what do we know about it for sure? The European Club for the Study of GLP-1 (EuCSGLP-1) has debated the latest ..
  80. pmc Sustained glucagon-like peptide 1 expression from encapsulated transduced cells to treat obese diabetic rats
    Daniel Moralejo
    Department of Comparative Medicine, University of Washington, Seattle, WA 98195, USA
    J Biosci Bioeng 111:383-7. 2011
    ..T2D is characterized by hyperglycemia and islet beta cell dysfunction. Glucagon-like peptide 1 (GLP-1) promotes β cell proliferation and neogenesis and has a potent insulinotropic effect...
  81. doi Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides
    Robert E Steinert
    Division of Gastroenterology, Department of Biomedicine, Clinical Research Center, University Hospital Basel, Basel, Switzerland
    Br J Nutr 105:1320-8. 2011
    ..In vitro, both carbohydrate sugars and artificial sweeteners (AS) stimulate the secretion of glucagon-like peptide-1 (GLP-1)...
  82. pmc Bone: incretin hormones perceiver or receiver?
    Ilaria Dicembrini
    Section of Endocrinology, Department of Clinical Pathophysiology, Careggi Teaching Hospital, University of Florence and Obesity Agency, 50127 Florence, Italy
    Exp Diabetes Res 2012:519784. 2012
    Novel incretin-based drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i), have been last introduced in the pharmacological treatment of type 2 diabetes...
  83. doi Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells
    Christine Wallrapp
    CellMed AG, a BTG Company, 63755 Alzenau, Germany
    J Microencapsul 30:315-24. 2013
    Glucagon-like peptide-1 (GLP-1) CellBeads are cell-based implants for the sustained local delivery of bioactive factors...
  84. doi Is there a place for incretin therapies in obesity and prediabetes?
    Jens Juul Holst
    The NNF Center for Basic Metabolic Research, Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Trends Endocrinol Metab 24:145-52. 2013
    ..the insulinotropic actions of the gut hormones gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) for the treatment of diabetes and include GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-..
  85. doi GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects
    José C Fernández-García
    Department of Endocrinology, Virgen de la Victoria University Hospital, Malaga, Spain Research Laboratory, Virgen de la Victoria University Hospital, Malaga, Spain Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition CIBERObn CB06 003, Instituto de Salud Carlos III, Madrid, Spain
    Clin Endocrinol (Oxf) 80:671-6. 2014
    Both glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) are gut hormones involved in energy homoeostasis. Obesity, insulin resistance and hyperglycaemia are significant confounders when GLP-1 and PYY secretion is assessed...
  86. pmc Oral processing effort, appetite and acute energy intake in lean and obese adults
    Richard D Mattes
    Purdue University, Department of Nutrition Science, West Lafayette, IN, USA Electronic address
    Physiol Behav 120:173-81. 2013
    ..appetitive sensations, energy intake, gastric emptying, GI transit time, and concentrations of glucose, insulin, GLP-1, ghrelin and pancreatic polypeptide...
  87. doi Evidence for paracrine/autocrine regulation of GLP-1-producing cells
    Camilla Kappe
    Karolinska Institutet, Department of Clinical Science and Education, Unit for Diabetes Research, Sodersjukhuset, Stockholm, Sweden
    Am J Physiol Cell Physiol 305:C1041-9. 2013
    Glucagon-like peptide-1 (GLP-1), secreted from gut L cells upon nutrient intake, forms the basis for novel drugs against type 2 diabetes (T2D)...
  88. doi Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion
    Serenella Salinari
    Department of Computer, Control, and Management Engineering Antonio Ruberti, University of Rome Sapienza, Rome, Italy
    Diabetes 63:1069-78. 2014
    ..Baseline and poststimulation levels of glucose, insulin, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured...
  89. doi Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption
    F L Wright
    Behavioural Neuroscience Laboratory, Institute of Psychological Sciences, University of Leeds, Leeds, LS2 9JT, UK, England
    Psychopharmacology (Berl) 231:3729-44. 2014
    The glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 potently suppresses food intake in animals and humans...
  90. pmc Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production
    Eszter Sélley
    2nd Department of Medicine and Nephrological Center, University of Pecs, Hungary, 1, Pacsirta St, H 7624 Pecs, Hungary
    Cardiovasc Diabetol 13:69. 2014
    It has been reported that GLP-1 agonist exenatide (exendin-4) decreases blood pressure. The dose-dependent vasodilator effect of exendin-4 has previously been demonstrated, although the precise mechanism is not thoroughly described...
  91. pmc The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis
    Xinfu Guan
    U S Department of Agriculture Agricultural Research Service, Children s Nutrition Research Center, Department of Pediatrics and Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Texas
    Am J Physiol Regul Integr Comp Physiol 307:R585-96. 2014
    ..and microbiota-derived metabolites (secondary bile acids and short chain fatty acids), glucagon-like peptides (GLP-1 and -2) are cosecreted from endocrine L cells in the gut and coreleased from preproglucagonergic neurons in the ..
  92. doi Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists
    Christopher A Lindamood
    University of Florida, College of Pharmacy, Gainesville, Florida
    Clin Ther 37:483-93. 2015
    The goal of this article was to review the safety, efficacy, and potential for utilization of the newly approved once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of type 2 diabetes.
  93. doi [Strategic considerations on the design and choice of animal models for non-clinical investigations of cell-based medicinal products]
    Jörg Lehmann
    Fraunhofer Institut für Zelltherapie und Immunologie IZI, Perlickstraße 1, 04103, Leipzig, Deutschland
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 58:1215-24. 2015
    ..The execution of non-clinical studies under the principles of good laboratory practice (GLP) increases the acceptance of the results by authorities and the scientific community.
  94. doi Hibiscus sabdariffa polyphenols prevent palmitate-induced renal epithelial mesenchymal transition by alleviating dipeptidyl peptidase-4-mediated insulin resistance
    Chien Ning Huang
    Department of Internal Medicine, Chung Shan Medical University Hospital, Number 110, Section 1, Chien Kuo North Road, Taichung 402, Taiwan and Institute of Medicine, Chung Shan Medical University, Number 110, Section 1, Chien Kuo North Road, Taichung 402, Taiwan
    Food Funct 7:475-82. 2016
    ..we reported HPE inhibited dipeptidyl-peptidase-4 (DPP-4, the enzyme degrades type 1 glucagon-like peptide (GLP-1)), which mediated insulin resistance signals leading to EMT...
  95. doi Pharmacologic stimulation of central GLP-1 receptors has opposite effects on the alterations of plasma FGF21 levels induced by feeding and fasting
    Katsunori Nonogaki
    Department of Diabetes Technology, Tohoku University Graduate School of Biomedical Engineering, Japan Electronic address
    Neurosci Lett 612:14-7. 2016
    ..Here we show the effects of liraglutide, a human glucagon-like-peptide-1 (GLP-1) receptor agonist, injected into the third cerebral ventricle on body weight and plasma FGF21 levels in free-..
  96. doi Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment
    Oleg Baranov
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetes Obes Metab 18:1100-1109. 2016
    ..To compare directly the clinical effects of vildagliptin and sitagliptin in patients with type 2 diabetes, with a special emphasis on incretin hormones and L-cell feedback inhibition induced by dipeptidyl peptidase (DPP-4) inhibition...
  97. ncbi A role for glucagon-like peptide-1 in the central regulation of feeding
    M D Turton
    Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
    Nature 379:69-72. 1996
    The sequence of glucagon-like peptide-1 (7-36) amide (GLP-1) is completely conserved in all mammalian species studied, implying that it plays a critical physiological role...
  98. ncbi Islet adaptation to insulin resistance: mechanisms and implications for intervention
    B Ahren
    Department of Medicine, Lund University, SE 221 84 Lund, Sweden
    Diabetes Obes Metab 7:2-8. 2005
    ..as glucose, free fatty acids, autonomic nerves, fat-derived hormones and the gut hormone glucagon-like peptide-1 (GLP-1)...
  99. pmc Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons
    Xiaosong Ma
    University Laboratory of Physiology, Oxford OX1 3PT, United Kingdom
    J Neurosci 27:7125-9. 2007
    Glucagon-like peptide 1 (GLP-1) is a potent inhibitor of food intake. GLP-1 receptor mRNA is densely expressed in hypothalamic arcuate nucleus (ARC) and precisely overlaps the area occupied by proopiomelanocortin (POMC) neurons...
  100. doi Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats
    P J Larsen
    Rheoscience, Copenhagen, Denmark
    Diabetes Obes Metab 10:301-11. 2008
    ..Severe insulin resistance and impaired pancreatic beta-cell function are pathophysiological contributors to type 2 diabetes, and ideally, antihyperglycaemic strategies should address both...
  101. doi A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis
    Jae Min Cho
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul 135 710, Republic of Korea
    Diabetes Res Clin Pract 91:72-9. 2011
    ..DA-1229 significantly reduced plasma DPP IV activity, and enhanced glucagon-like peptide 1 (GLP-1) levels...

Research Grants74

  1. Discovery metabolite profiling of the prolyl peptidases
    Alan Saghatelian; Fiscal Year: 2009
    ..Furthermore, the application of DMP to peptidases will demonstrate the generality of this approach for the future characterization of medically relevant enzymes and signaling pathways. ..
  2. Surgical amelioration of type 2 diabetes: Hormones, microbiota and mitochondria
    PETER J contact HAVEL; Fiscal Year: 2010
    ..of the distal small intestine resulting in increased secretion of gut hormones such as glucagon-like peptide-1 (GLP-1) and peptide-YY (PYY)...
  3. Discovery of biased small molecule agonists of the GLP-1 receptor for treatment o
    JOHAN KARL ENQUIST; Fiscal Year: 2013
    ..Glucagon-like peptide 1 (GLP-1) and its receptor have emerged as one of the most promising avenues for intervention...
  4. A PROOF-OF-CONCEPT CLINICAL TRIAL OF XENIN-25 IN THE TREATMENT OF TYPE 2 DIABETES
    Burton M Wice; Fiscal Year: 2010
    ..Modulating the action or plasma concentrations of Glucagon- Like Peptide-1 (GLP-1), an intestinal peptide produced by intestinal L cells, is the basis for the action of two novel treatments of ..
  5. Burton M Wice; Fiscal Year: 2014
    ..Glucagon-Like Peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are the two major incretins most extensively studied to ..
  6. Glucose lowering effect of metformin and sitagliptin in adolescents with Type 1
    Luisa M Rodriguez; Fiscal Year: 2013
    ..is an oral hypoglycemic agent that acts as an incretin enhancer by increasing the circulation of endogenous active GLP-1...
  7. Link of beta cell proliferation and type 2 diabetes to epigenetic regulation
    Xianxin Hua; Fiscal Year: 2013
    ..Our recent findings suggest that menin interplays with glucagon-like peptide 1 (GLP-1) signaling pathway, which promotes beta cell regeneration, to regulate gene transcription...
  8. The role of phosphorylation in regulating the antidiabetic effects of O3FAR-1
    Nader H Moniri; Fiscal Year: 2013
    ..interest due to its ability to stimulate intestinal secretion of the incretin hormone glucagon-like-peptide-1 (GLP-1), which stimulates pancreatic b-cells leading to insulin secretion and subsequently, decreases in blood glucose...
  9. George G Holz; Fiscal Year: 2016
    An emerging theme in experimental therapeutics concerns the use of glucagon-like peptide-1-(7-36)- amide (GLP-1) and its synthetic peptide analogs (the "incretin mimetics") to lower levels of blood glucose in Type 2 diabetic subjects...
  10. Automated Intestinal Electrical Stimulation for Diabetes
    Jiande Chen; Fiscal Year: 2013
    ..it reduces food intake and nutrient absorption, inhibits gastric ghrelin and increases glucagon-like peptide (GLP-1) in the postprandial state...
  11. Role of GLP-1 in Congenital Hyperinsulinism
    DIVA DEL CARMEN DE LEON; Fiscal Year: 2010
    Project Summary/Abstract Description This is a translational research study of the role of glucagon-like peptide-1 (GLP-1) in congenital hyperinsulinism (CHI), the most frequent cause of persistent hypoglycemia in children...
  12. The role of GLP-1 in normal and abnormal glucose tolerance
    DAVID A D'ALESSIO; Fiscal Year: 2013
    ..The overall goal of this proposal is to determine the role of the regulatory peptide glucagon-like peptide 1 (GLP-1) to regulate glucose tolerance in nondiabetic persons and patients with T2DM...
  13. Long Acting Native GLP-1 formulations for Type 1 Diabetes
    Elijah Bolotin; Fiscal Year: 2009
    ..finding that islet cells can be regenerated in diabetic animals by the peptide hormone Glucagon- like peptide 1 (GLP-1) has raised the exciting possibility of a new approach for a cure...
  14. Novel Glucagon Modulators and the Closed Loop System
    Rubina A Heptulla; Fiscal Year: 2012
    ..Glucagon suppressors such as the amylin analog, pramlintide, and the glucagon like peptide-1 (GLP-1) mimetic, exenatide, are new agents approved for use in diabetes...
  15. The Role of the Cdc42-Pak1 Signaling Pathway in the Incretin Effect
    STEPHANIE MICHELLE YODER; Fiscal Year: 2013
    ..The two incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from intestinal K and L cells, respectively, in response to nutrient ingestion...
  16. John Kinzell; Fiscal Year: 2014
    ..The third objective is to manufacture a GLP batch of non-aqueous glucagon to demonstrate compatibility in a standard 3 mL drug cartridge format designed for ..
  17. Paresh Dandona; Fiscal Year: 2016
    ..We, therefore, investigated the effect of liraglutide, a GLP-1 analog in combination with insulin given as a continuous subcutaneous infusion of insulin (CSII) in such patients...
  18. Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
    Frank A Anania; Fiscal Year: 2010
    ..At present there is limited therapy for fatty liver disease. Glucagon-like peptide (GLP-1) is a naturally occurring gut peptide secreted by the L cells of the small intestine...
  19. Sakeneh Zraika; Fiscal Year: 2016
    ..Like dipeptidyl peptidase-4 (DPP-4), NEP can degrade and inactivate glucagon-like peptide-1 (GLP-1), a glucose-dependent insulinotropic peptide secreted by intestinal L cells and islet ? cells...
  20. EDWIN KERRY JACKSON; Fiscal Year: 2016
    ..DPPIV metabolizes incretin hormones [e.g., glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)], and consequently DPPIV inhibitors raise circulating levels ..
  21. Johnathan D Tune; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Effects of glucagon-like peptide-1 (GLP-1) on the heart have been recently recognized, but little is known regarding the cardiovascular physiology of this incretin hormone...
  22. Sweet taste receptors and glucose metabolism in healthy and T2DM humans
    Karen L Teff; Fiscal Year: 2012
    ..signaling elements are co-expressed in the intestinal L-cells which secrete the hormone, glucagon-like peptide (GLP);during food ingestion, stimulation of the STR also elicits the release of GLP...
  23. Mechanisms of Glycemic Improvement Following Gastrointestinal Surgery
    David R Flum; Fiscal Year: 2013
    ..Plasma levels of GLP-1, GIP...
  24. Novel Role for CNS GLP in Glucose Homeostasis
    Darleen A Sandoval; Fiscal Year: 2010
    ..A wide range of evidence points to an important role for glucagon-like peptide-1 (GLP-1) in the control of glucose levels in the blood and this has resulted in the recent approval of long-acting GLP-1 ..
  25. Darleen A Sandoval; Fiscal Year: 2014
    ..This raises the possibility that CNS mechanisms could link obesity and T2DM. Glucagon-like peptide-1 (GLP-1), secreted by the intestine, is a potent stimulus for insulin secretion and is essential for normal glucose ..
  26. Rational Design of Peptidomimetics Targeting Glucagon-Like Peptide-1 Receptors
    Jung Mo Ahn; Fiscal Year: 2010
    ..To demonstrate proof of concepts, we have chosen a peptide hormone, glucagon like peptide-1 (GLP-1) that plays an important physiological role in glucose homeostasis through stimulating insulin secretion and ..
  27. Matthew R Hayes; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): The proposed research focuses on the neuropeptide glucagon-like peptide-1 (GLP-1) and its role in controlling for food intake and body weight through action in the central nervous system (CNS)...
  28. Neural mechanism of glucagon-like-peptide-1 receptor-mediated nausea /malaise
    Matthew R Hayes; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The proposed research focuses on the neuropeptide glucagon-like-peptide-1 (GLP-1) and its role in controlling for food intake and body weight...
  29. Development of cAMP Biosensor, High Content Imaging, and Functional GLP-1R aSSAYS
    Philip LoGrasso; Fiscal Year: 2010
    ..goal of this work is to develop a series of novel high throughput assays for the glucagon-like peptide 1 receptor (GLP-1R) which are capable of driving a drug discovery program for this clinically validated target of type II diabetes ..
  30. 8th International Symposium for VIP, PACAP & Related Peptides
    Victor May; Fiscal Year: 2007
    ..related peptides, including growth hormone releasing hormone (GHRH), secretin, glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, and glucose-dependent insulinotropic peptide (GIP) is more distant but in aggregate, members of PACAP/..
  31. Beta-cell Proliferation
    Fredric E Wondisford; Fiscal Year: 2013
    ..The incretin hormone glucagon-like peptide-1 (GLP-1) stimulates murine pancreatic [unreadable]-cell proliferation...
  32. Link of beta cell proliferation and type 2 diabetes to epigenetic regulation.
    Xianxin Hua; Fiscal Year: 2010
    ..Our recent findings suggest that menin interplays with glucagon-like peptide 1 (GLP-1) signaling pathway, which promotes beta cell regeneration, to regulate gene transcription...
  33. Modulation of insulin and glucagon secretion by GPCR ligands
    TARA ASHLEY SCHWETZ; Fiscal Year: 2011
    ..This is especially significant considering GPCR ligands (i.e. GLP-1 analogs) have emerged as a promising treatment of Type-2 diabetes...
  34. Frank A Anania; Fiscal Year: 2016
    ..We have found that the naturally occurring hormone glucagon-like peptide 1 (GLP-1) has the capacity to significantly reduce hepatocyte steatosis in human cells...
  35. Jenny Tong; Fiscal Year: 2016
    ..In contrast, ghrelin induces hyperglycemia with hyperinsulinemia and increased glucagon-like peptide 1 (GLP-1) secretion following an orally ingested test meal...
  36. Diego V Bohórquez; Fiscal Year: 2014
    ..are at the forefront of diabetes and obe- sity research: 1) the insulin-stimulating glucagon-like peptide 1 (GLP-1);and, 2) the satiety-inducing peptide tyrosine tyrosine (PYY)...
  37. Jae W Lee; Fiscal Year: 2016
    ..activating enzyme type 2 iodothyronine deiodinase'(D2) and to enhance secretion of glucagon-like peptide-1 (GLP-1), an insulin secretagogue, thereby resulting in enhanced energy expenditure and improved glucose homeostasis...
  38. Scott C Thomson; Fiscal Year: 2014
    ..A more novel effector of proximal reabsorption is the incretin, glucagon-like peptide 1(GLP-1), which has outstanding potential as a proximal diuretic...
  39. Nutritional and Hormonal Mechanisms of Intestinal Adaptation
    Denise M Ney; Fiscal Year: 2011
    ..whey protein, liquid diet) in rats with SBS given PN in combination with a low dose of glucagon-like peptide-2 (GLP-2) to optimize intestinal adaptation, and to identify the underlying mechanisms...
  40. Functional characterization of endocrine taste cells
    Robert F Margolskee; Fiscal Year: 2013
    ..signaling elements to GI chemosensation comes from the observation that 1-gustducin knockout mice do not secrete GLP-1 (Glucagon-Like Peptide 1) from their enteroendocrine cells in response to infusion of glucose into the gut lumen -..
  41. Secretagogue induced mechanisms regulating islet electrical activity
    DAVID AARON JACOBSON; Fiscal Year: 2012
    ..Glucagon-like peptide 1 (GLP-1) stimulates islet cAMP production and augments postprandial insulin secretion...
  42. Jill Carmody; Fiscal Year: 2014
    ..Among these hormones, glucagon-like peptide-1 (GLP-1), an incretin hormone that promotes insulin release and inhibits food intake, is particularly attractive as a ..
  43. Parenteral Nutrition: Intestinal Metabolism/Adaptation
    Denise Ney; Fiscal Year: 2009
    ..resection models that show differential mucosal growth in response to luminal nutrients and endogenous levels of GLP-2...
  44. Pediatric Type 1 diabetes: Intervention Trials With Glucagon Suppressors
    Rubina A Heptulla; Fiscal Year: 2010
    ..Glucagon suppressors such as the amylin analog, pramlintide, and the glucagon like peptide-1 (GLP-1) analog, exenatide, are new agents approved for use in adults with diabetes...
  45. KENNETH BER MARGULIES; Fiscal Year: 2016
    ..we propose a novel clinical trial examining the therapeutic efficacy of recombinant glucagon-like peptide (GLP-1) in patients with severe systolic HF...
  46. Hormonal and neural control of insulin secretion following gastric bypass surgery
    Marzieh Salehi; Fiscal Year: 2013
    ..not understood, recent studies suggest that increased secretion of Gl hormones, primarily glucagon-like peptide 1 (GLP-1), may contribute to enhanced insulin secretion in general, and to a greater extent in patients with hypoglycemia...
  47. STEVEN EMANUEL KAHN; Fiscal Year: 2015
    ..Incretin-related medications, including glucagon-like peptide-1 receptor agonists (GLP-1RA), improve islet function, but their ability to prevent diabetes and slow its progression is unknown...
  48. Franck Mauvais-Jarvis; Fiscal Year: 2014
    ..We also propose to explore the synergy between estrogen and glucagon-like peptide-1 (GLP-1) in human islet survival and revascularization in a diabetic mouse model of PIT using a novel compound combining ..
  49. Thiol-Ene Click Hydrogels for in situ Cell Expansion and Differentiation
    Chien Chi Lin; Fiscal Year: 2012
    ..recruitment of basic fibroblast growth factor (bFGF), and timely conjugation of glucagon-like peptide 1 (GLP-1)...
  50. Role of Oral vs Injectable Glucagon Suppressors
    Rubina A Heptulla; Fiscal Year: 2013
    ..For the last decade we have investigated various glucagon suppressors'amylin, GLP-1 and sitagliptin to combat this problem...
  51. REDUCIBLE POLYAMIDO ETHYLENIMINE FOR GLP-1 PLASMID DELIVERY
    Sung Wan Kim; Fiscal Year: 2012
    ..It has been reported that glucagon-like peptide 1 (GLP-1) administration completely normalized blood glucose in type 2 diabetic patients...
  52. Novel PPAR-Independent Peroxisome Proliferators for Type 2 Diabetes
    LIDIA NIEROBISZ; Fiscal Year: 2011
    ..The insulin-enhancing incretins (e.g.: exendin/Byetta" GLP-1 mimetics) are a newly approved class of peptide drugs that must be administered by subcutaneous needle injection...
  53. Novel Small Molecule Therapeutics to Treat Obesity
    SUSAN MEDGHALCHI; Fiscal Year: 2010
    ..a 5-day rat TK study, [5] undergo cardiac testing in conscious dogs, and [6] conclude a formal 28-day preclinical GLP rat toxicity study...
  54. Steven D Munger; Fiscal Year: 2016
    ..We have recently reported that the gut hormone, glucagon-like peptide 1 (GLP-1), can modulate sweet taste sensitivity...
  55. L-type Ca2+ Channel Modulation of Beta Cell Function
    GREGORY HOWARD HOCKERMAN; Fiscal Year: 2012
    ..2 channels can mediate glucose-stimulated insulin secretion. Insulin secretion is potentiated by the hormone GLP-1, by its binding to the GLP-1 receptor...
  56. ELIZABETH GENEVIEVE MIETLICKI-BAASE; Fiscal Year: 2014
    ..One potential target for weight loss therapies is the glucagon-like peptide-1 (GLP-1) system...
  57. Mechanisms of alimentary chemosensation
    Steven D Munger; Fiscal Year: 2013
    ..the role of two hormones expressed in taste cells and in the digestive system, glucagon-like peptide-1 (GLP-1) and glucagon, in the modulation of taste sensitivity...
  58. Neuroendocrinology of energy balance control: role of glucagon-like-peptide-1
    Matthew R Hayes; Fiscal Year: 2012
    ..The research plan focuses on the neuropeptide glucagon-like-peptide-1 (GLP-1) and its role in controlling for food intake, body weight regulation and glucose homeostasis...
  59. DIVA DEL CARMEN DE LEON; Fiscal Year: 2015
    ..Preliminary preclinical and clinical data suppor the use of the GLP-1 receptor antagonist, exendin-(9-39) as a novel therapeutic approach...
  60. Delivery of Peptide Therapeutics by Molecular Release Depots
    Ashutosh Chilkoti; Fiscal Year: 2011
    ..We have chosen the delivery of Glucagon like peptide-1 (GLP- 1) as a clinically relevant test case to establish proof-of-concept of the Molecular Release Depot platform ..
  61. Comparative Effectiveness of Medical Therapy vs. Bariatric Surgery for Obese T2DM
    DAVID BRADLEY contact LAUTZ; Fiscal Year: 2010
    ..Gastrointestinal hormones including incretins (GLP-1, GIP) and appetite regulating peptides (ghrelin, PYY, leptin) will be compared...
  62. Bacterially-Secreted GLP-1 Induced Reprogramming of Intestinal Cells as a Treatme
    John C March; Fiscal Year: 2012
    ..cells can be programmed into glucose-responsive insulin-secreting cells by exposing them to an otherwise inactive GLP-1 peptide...
  63. Liver Glycogen in Control of Plasma Glucose
    Katarina Borer; Fiscal Year: 2009
    ..responsible for EAAF and is mediated by increased secretion of insulinotropic gut peptides glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), that increase insulin/glucagon ratio and reduce ..
  64. ROLE OF GLP-I-7-37 IN INSULIN SECRETION
    Svetlana Mojsov; Fiscal Year: 1992
    ..One of these glucagon-like peptides, GLP-I is liberated from proglucagon in the intestinal L cells and the pancreatic islets...
  65. Regional Biocontainment Laboratory
    Charles Bailey; Fiscal Year: 2007
    ..aerobiology, and testing of vaccines and therapeutics against aerosol challenge in a Good Laboratory Practices (GLP) environment...
  66. Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn
    George Cox; Fiscal Year: 2009
    ..During Phase I of the SBIR grant, we developed a GLP (Good Laboratory Practices) manufacturing process and supporting assay methods to produce material for GLP ..
  67. REGULATION OF INSULIN SECRETION IN NON-ISLET CELLS
    ALVIN POWERS; Fiscal Year: 2001
    ..regulated insulin secretion (lack GLUT2 glucose transporter, glucokinase (GK), glucagon-like peptide-I (GLP-1) receptor, and glucose-dependent insulin releasing polypeptide (GIP) receptor)...
  68. Understanding the role of bile as a mechanism for improved glucose homeostasis fo
    APRIL DAWN STRADER; Fiscal Year: 2010
    ..ileum results in dramatically enhanced secretion of two important ileal produced hormones, glucagon like peptide-1 (GLP-1) and peptide- YY (PYY), the former believed to be critical in the euglycemic effect...
  69. GM-CSF analogs for treating acute radiation syndrome
    GEORGE NORBERT COX; Fiscal Year: 2010
    ..In addition we will optimize processes for manufacture of the human PEG-GM-CSF protein under GLP (Good Laboratory Practices) conditions and measure the safety profile and pharmacokinetic properties of the protein ..
  70. Pre-Clinical HPV16 Antiviral Compound Development
    Christopher Fisher; Fiscal Year: 2010
    ..in close collaboration with NanoVir consultants and the Stanford Research Institute, International (SRI), a GLP-approved facility with considerable history and expertise in the development of vaginally-delivered drugs and ..
  71. Long-Acting G-CSF analogs for treating acute radiation syndrome
    GEORGE NORBERT COX; Fiscal Year: 2010
    ..In addition we will optimize processes for manufacture of the protein under GLP (Good Laboratory Practices) conditions and measure the safety profile and pharmacokinetic properties of the protein ..
  72. A nanoparticle prognosticator of chemotherapy outcomes
    Russell Lebovitz; Fiscal Year: 2009
    ..We anticipate producing NCTX at the 50L scale under GLP conditions within the next 12 months, and pursuing an IND application shortly afterwards...